Abstract
Bezafibrate has been shown in several studies to have effective hypocholesterolemic and hypotriglyceridemic activity |1–6|. Thus the drug may be of benefit in primary and secondary prevention of atherosclerosis. From this point of view, two aspects seem to be of particular interest. The first one is the effect of the drug on lipoprotein subfractions that are believed to play different roles in atherogenesis. The second one is the long-term effectiveness and safety of bezafibrate therapy since the hypolipidemic treatment must be continued for years or decades.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
